• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - Product Image

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  • Published: February 2012
  • 63 pages
  • GlobalData

FEATURED COMPANIES

  • Amgen Inc.
  • F. Hoffmann-La Roche
  • GlaxoSmithKline plc
  • Grifols Biologicals Inc.
  • MORE

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. The report identifies the key trends shaping and driving the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Introduction
2.1 Overview
2.2 Classification of Idiopathic Thrombocytopenic Purpura
2.3 Pathophysiology of Chronic Idiopathic Thrombocytopenic Purpura
2.4 Epidemiology
2.5 Clinical Symptoms
2.6 Diagnosis and Management of Idiopathic Thrombocytopenic Purpura
2.7 Treatment of Idiopathic Thrombocytopenic Purpura
2.8 GlobalData Pipeline Report Guidance
3 Idiopathic Thrombocytopenic Purpura Therapeutics - Market Characterization
3.1 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Global
3.2 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Global
3.3 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - the US
3.4 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - the US
3.5 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - the UK
3.6 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - the UK
3.7 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - France
3.8 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - France
3.9 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Germany
3.10 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Germany
3.11 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Italy
3.12 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Italy
3.13 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Spain
3.14 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Spain
3.15 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Japan
3.16 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Japan
3.16.1 Drivers for the Idiopathic Thrombocytopenic Purpura Therapeutics Market
3.16.2 Barriers for the Idiopathic Thrombocytopenic Purpura Therapeutics Market
3.17 Key Events Impacting the Future Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Idiopathic Thrombocytopenic Purpura Therapeutics Market
4.3.1 Nplate (romiplostim)
4.3.2 Promacta/Revolade (eltrombopag)
4.4 Key Takeaway
5 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Pipeline Assessment
5.1 Overview
5.1.1 Strategic Pipeline Assessment
5.2 Idiopathic Thrombocytopenic Purpura Therapeutics Pipeline Analysis - Pipeline by Clinical Phases of Development
5.2.1 ITP Therapeutics - Phase III Clinical Pipeline
5.2.2 Idiopathic Thrombocytopenic Purpura Therapeutics - Phase II Clinical Pipeline
5.2.3 Idiopathic Thrombocytopenic Purpura Therapeutics - Phase I/II Clinical Pipeline
5.2.4 Idiopathic Thrombocytopenic Purpura Therapeutics - Pre-Clinical Pipeline
5.3 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Clinical Pipeline by Mechanism of Action
5.4 Idiopathic Thrombocytopenic Purpura Technology Trends Analytical Framework
5.5 Molecule Profile for Late-Stage Drugs under Clinical Development
5.5.1 IGIV3I 10% Grifols
5.5.2 Mabthera (rituximab)
5.6 Key Takeaway
6 Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Idiopathic Thrombocytopenic Purpura Therapeutics Clinical Trials
7 Idiopathic Thrombocytopenic Purpura Therapeutics - Strategic Assessment
7.1 Future Market Competition Scenario
8 Idiopathic Thrombocytopenic Purpura Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 F. Hoffmann-La Roche
8.2.2 Grifols Biologicals Inc.
8.2.3 Amgen Inc.
8.2.4 GlaxoSmithKline plc
8.2.5 Other Companies in the Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011
9 Idiopathic Thrombocytopenic Purpura Therapeutics - Licensing and Partnership Deals
10 Idiopathic Thrombocytopenic Purpura Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Classification of Idiopathic Thrombocytopenic Purpura
Table 2: Prevalence of Idiopathic Thrombocytopenic Purpura, 2011
Table 3: Diagnostic Tools for Idiopathic Thrombocytopenic Purpura
Table 4: Treatment of Idiopathic Thrombocytopenic Purpura according to Haematological Societies Guidelines
Table 5: Characteristics of Existing Major Drugs for Idiopathic Thrombocytopenic Purpura
Table 6: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Table 7: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Table 8: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Revenue ($m), 2006 - 2011
Table 9: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Revenue ($m), 2011 - 2019
Table 10: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Revenue ($m), 2006 - 2011
Table 11: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Forecast ($m), 2011 - 2019
Table 12: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Revenue ($m), 2006 - 2011
Table 13: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Forecast ($m), 2011 - 2019
Table 14: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Table 15: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Forecast ($m), 2011 - 2019
Table 16: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Table 17: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Forecast ($m), 2011 - 2019
Table 18: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Table 19: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Forecast ($m), 2011 - 2019
Table 20: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Revenue ($m), 2006 - 2011
Table 21: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Forecast ($m), 2011 - 2019
Table 22: Idiopathic Thrombocytopenic Purpura Therapeutics - Phase III Pipeline
Table 23: Idiopathic Thrombocytopenic Purpura Therapeutics - Phase II Pipeline
Table 24: Idiopathic Thrombocytopenic Purpura Therapeutics - Phase I/II Pipeline
Table 25: Idiopathic Thrombocytopenic Purpura Therapeutics - Pre-Clinical Pipeline
Table 26: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Country, 2011
Table 27: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Phase, 2011
Table 28: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Status, 2011
Table 29: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Overall Sponsors, 2011
Table 30: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Prominent Sponsors, 2011
Table 31: Idiopathic Thrombocytopenic Purpura Therapeutics - Top Companies Participating in Clinical Trials, 2011
Table 32: F. Hoffmann-La Roche - Idiopathic Thrombocytopenic Purpura Pipeline, 2011
Table 33: Grifols Biologicals Inc.- Idiopathic Thrombocytopenic Purpura Pipeline, 2011
Table 34: Amgen Inc. - Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011
Table 35: GlaxoSmithKline plc - Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011
Table 36: Other Companies in the Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011
Table 37: Idiopathic Thrombocytopenic Purpura Therapeutics: Licensing and Partnership Deals

1.2 List of Figures
Figure 1: Pathophysiology of Chronic Idiopathic Thrombocytopenic Purpura
Figure 2: Management Algorithm for Idiopathic Thrombocytopenic Purpura
Figure 3: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 4: ITP Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Figure 5: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Revenue ($m), 2006 - 2011
Figure 6: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Forecast ($m), 2011 - 2019
Figure 7: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Revenue ($m), 2006 - 2011
Figure 8: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Forecast ($m), 2011 - 2019
Figure 9: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Revenue ($m), 2006 - 2011
Figure 10: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Forecast ($m), 2011 - 2019
Figure 11: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Figure 12: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Forecast ($m), 2011 - 2019
Figure 13: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Figure 14: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Forecast ($m), 2011 - 2019
Figure 15: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Figure 16: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Forecast ($m), 2011 - 2019
Figure 17: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Revenue ($m), 2006 - 2011
Figure 18: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Forecast ($m), 2011 - 2019
Figure 19: Idiopathic Thrombocytopenic Purpura Therapeutics, Key Events Impacting Future Market
Figure 20: Opportunity and Unmet Need in the First-line Treatment of Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011
Figure 21:Opportunity and Unmet Need in the Second-line Treatment of Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011
Figure 22: Idiopathic Thrombocytopenic Purpura Therapeutics Market - Strategic Competitor Assessment, 2011
Figure 23: Idiopathic Thrombocytopenic Purpura Therapeutics - Pipeline by Phase of Clinical Development, 2011
Figure 24: Idiopathic Thrombocytopenic Purpura Therapeutics, Clinical Pipeline by Mechanism of Action, 2011
Figure 25: Idiopathic Thrombocytopenic Purpura Therapeutics, Technology Trends Analytics Framework, 2011
Figure 26: Idiopathic Thrombocytopenic Purpura Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 27: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Country, 2011
Figure 28: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Phase, 2011
Figure 29: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Status, 2011
Figure 30: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Overall Sponsors, 2011
Figure 31: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical trials by Prominent Sponsors, 2011
Figure 32: Top Companies Participating in Idiopathic Thrombocytopenic Purpura Therapeutics Clinical Trials, 2011
Figure 33: Idiopathic Thrombocytopenic Purpura Therapeutics, Strategic Assessment, 2011
Figure 34: Idiopathic Thrombocytopenic Purpura Therapeutics Market - Future Players, 2011
Figure 35: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global ITP therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ITP therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Idiopathic Thrombocytopenic Purpura Therapeutics Market is Forecast to Show Moderate Growth until 2019

GlobalData’s analysis estimated the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market was worth $299.06m in 2011. It is forecast to show moderate growth at a Compound Annual Growth Rate (CAGR) of 5.38% for the next eight years to reach $454.95m by 2019. The market witnessed significant growth during 2006-2011 owing to the launch of Nplate (romiplostim) in 2008 in the US and in Europe in 2009. In addition to this, Promacta/Revolade (eltrombopag) was launched in the US in 2009 and in Europe in 2010. The moderate growth in the ITP therapeutics market can be attributed to the strong performance of the both of these products during the forecast period. The expected launch of IGIV3I 10% Grifols will also contribute to the growth of the market during the forecast period.

The Idiopathic Thrombocytopenic Purpura Therapeutics Market has Low Unmet Need with Potential for Cost Effective Therapies with Better Safety Profiles

The current ITP therapeutics market consists of various generic and few branded products. The major classes of drugs used for the treatment of ITP include corticosteroids, Intravenous Immunoglobulins (IVIG), anti-D immunoglobulins and Thrombopoetin Receptor Agonists (TPO-RA). Corticosteroids, IVIG, anti-D immunoglobulins and IVRhIG are considered to be the first-line treatment options and Imuran (azathioprine), cyclosporine A, TPO-RA and Mabthera (off-label) are used as second-line therapeutic agents for ITP. The standard treatment therapies are unable to significantly modify the natural course of the disease by avoiding its chronic evolution. However, the thrombopoetin receptor agonists, Promacta/Revolade and Nplate, represent a major advancement in ITP treatment. The traditional therapies for ITP focus on reducing platelet destruction; whereas thrombopoietic agents have the ability to increase platelet counts of patients with ITP. These agents have changed the treatment paradigm for ITP.

F. Hoffmann-La Roche
Grifols Biologicals Inc.
Amgen Inc.
GlaxoSmithKline plc

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos